MB-05032 is a GNG inhibitor that targets the AMP-binding site of fructose-1,6-bisphosphatase (FBPase) with an IC50 of 16 nM; it demonstrates dose-dependent glucose-lowering effects in young and aged Zucker diabetic fatty (ZDF) rats with mild to overt diabetes following oral administration.